ArticleAntibiotics (Basel, Switzerland)2026
Comparative Efficacy of Tulathromycin and Ceftiofur for Treating Undifferentiated BRDC and Tulathromycin Metaphylaxis in Dairy Cattle.
Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND/
objectivesBovine respiratory disease complex (BRDC) is commonly treated empirically, as etiological diagnosis is often impractical under field conditions. Comparative evidence on antimicrobial efficacy in undifferentiated BRDC remains limited. This study aimed to compare the therapeutic efficacy of tulathromycin and ceftiofur for treating undifferentiated BRDC in dairy cattle and to describe hematological and biochemical responses following a tulathromycin metaphylaxis program implemented during the seasonal high-PM2.5 period in northern Thailand.
methodsThirty-eight Holstein-Friesian cattle with clinical BRDC were randomly assigned to receive tulathromycin (2.5 mg/kg, single subcutaneous dose;
resultsCure rates were comparable between the tulathromycin and ceftiofur groups (90.0% vs. 88.9%), with similar case fatality rates (10.0% vs. 11.1%). No significant between-group differences were observed for clinical, hematological, or biochemical parameters. Both treatments resulted in significant within-group clinical and hematological improvement. During the metaphylaxis trial, no animals developed clinical BRDC; however, significant differences were observed in selected hematological parameters among injection groups.
conclusionsTulathromycin and ceftiofur demonstrated comparable efficacy for treating undifferentiated BRDC in dairy cattle under field conditions. In the metaphylaxis component, conducted during the seasonal high-PM2.5 period, the absence of clinical BRDC cases did not allow for evaluation of preventive efficacy. Nevertheless, differences in selected blood parameters were observed among injection groups and should be interpreted cautiously, warranting further investigation in studies incorporating low- and high-PM2.5 comparisons.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.